Evidence map›Paper›PMID 38894710›Full record

ArticleResearch and reports in urology2024

Neuroendocrine Carcinoma of the Bladder: A Case Report.

Pan Gao, Xinyu Li, Ziqiu He, Yifan Xu, Zhi Zhang

Abstract readCase Reports
In one paragraph

Article in Research and reports in urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pan Gao *Department of Urology, Second People's Hospital of Yichang, Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, People's Republic of China.ORCID 0000-0003-4314-7929
Xinyu Li *Department of Urology, Second People's Hospital of Yichang, Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, People's Republic of China.
Ziqiu HeDepartment of Urology, Second People's Hospital of Yichang, Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, People's Republic of China.
Yifan XuDepartment of Pathology, Second People's Hospital of Yichang, Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, People's Republic of China.
Zhi ZhangDepartment of Urology, Second People's Hospital of Yichang, Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary bladder large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive neoplasm with high recurrence rates and poor prognosis. Traditional management has heavily relied on radical cystectomy, which, despite its aggressiveness, often results in unsatisfactory outcomes. Emerging evidence suggests the potential for less invasive, bladder-sparing approaches, yet detailed reports and long-term outcomes remain scarce. We report a groundbreaking case of a 59-year-old male diagnosed with primary bladder LCNEC, managed through a pioneering bladder-sparing multimodal treatment. This novel strategy included transurethral resection followed by a tailored chemoradiation protocol, resulting in exceptional disease control and preservation of bladder function over a 20-month follow-up period, without evidence of recurrence. This case underscores the viability of bladder conservation strategies as a legitimate alternative to radical cystectomy for managing LCNEC, presenting a beacon of hope for patients wishing to preserve bladder functionality. It prompts a reevaluation of traditional treatment paradigms and advocates for further research into multimodal, organ-sparing approaches for this challenging malignancy.

Indexed as

bladder conservationEP regimenLCNECradiotherapysecondary transurethral resectionTURBT

Identifiers

PMID38894710
PMCPMC11184159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.